Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

Patrick Borgen, MD
Published Online: Monday, April 8, 2013
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Of the 20,000 human genes, about 4,000 are protected under patent or intellectual property rights, Borgen says, making BRCA1 and BRCA2 not all that unique. The American Civil Liberties Union has filed lawsuits arguing that these patents infringe upon the rights of researcher, geneticists, and patients.

As a practicing physician, Borgen has done research with BRCA1 and BRCA2 and has never been impeded by Myriad Genetics. In some ways, Borgen feels that physicians are lucky to have a singe reference laboratory to trust.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
$auto_registration$